{"id":70733,"date":"2026-05-12T10:13:05","date_gmt":"2026-05-12T10:13:05","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70733"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"ghrp-6","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/ghrp-6\/","title":{"rendered":"GHRP-6 Acetato"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 o Acetato de GHRP-6?<\/h3>\n<p style=\"margin: 0;\"><strong>GHRP-6 Acetato<\/strong> (Growth Hormone Releasing Peptide 6) is a 6-amino-acid synthetic hexapeptide and one of the original growth hormone secretagogues, developed by Bowers and colleagues as the second-generation member of the GHRP series. It acts on the growth hormone secretagogue receptor (GHS-R1a) \u2014 the same receptor as endogenous ghrelin \u2014 producing pulsatile GH release alongside appetite stimulation. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">87616-84-0 (GHRP-6 base livre); fornecido na forma de sal de acetato<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>46<\/sub>H<sub>56<\/sub>N<sub>12<\/sub>O<sub>6<\/sub> (base livre; sal de acetato adiciona CH<sub>3<\/sub>Contrai\u00e3o COOH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">873,02 Da (base livre)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2<\/sub> (HwAWfK-NH<sub>2<\/sub>, 6 amino\u00e1cidos; cont\u00e9m D-Trp na posi\u00e7\u00e3o 2 e D-Phe na posi\u00e7\u00e3o 5 para estabilidade proteol\u00edtica; extremidade C-terminal amidada)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sal de acetato liofilizado (p\u00f3 branco a branco-acinzentado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar no prazo de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de utiliza\u00e7\u00e3o mais curtos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 o Acetato de GHRP-6?<\/h2>\n<p><strong>GHRP-6<\/strong> (Growth Hormone Releasing Peptide 6) is a 6-amino-acid synthetic hexapeptide and one of the canonical members of the growth hormone secretagogue (GHS) peptide class. It was developed by Cyril Y. Bowers and colleagues at Tulane University as part of a structure-activity relationship programme designed to identify small peptides capable of stimulating pulsatile growth hormone release from the anterior pituitary \u2014 work that ultimately led to the discovery of the growth hormone secretagogue receptor and, indirectly, to the identification of endogenous ghrelin as its natural ligand in 1999 by Kojima et al. (Nature). The acetate counterion is used in pharmaceutical-grade lyophilization because it improves long-term peptide stability and aqueous solubility without altering pharmacology. The well-characterised sequence is HwAWfK-NH<sub>2<\/sub> (onde as letras min\u00fasculas denotam res\u00edduos de amino\u00e1cidos D), peso molecular 873,02 Da, f\u00f3rmula emp\u00edrica C<sub>46<\/sub>H<sub>56<\/sub>N<sub>12<\/sub>O<sub>6<\/sub>. As duas substitui\u00e7\u00f5es de amino\u00e1cidos D (D-Trp na posi\u00e7\u00e3o 2 e D-Phe na posi\u00e7\u00e3o 5) conferem resist\u00eancia \u00e0s proteases end\u00f3genas e prolongam a meia-vida in vivo em rela\u00e7\u00e3o aos an\u00e1logos com todos os amino\u00e1cidos L. A extremidade C-terminal \u00e9 amidada, o que \u00e9 essencial para a atividade do recetor. O GHRP-6 n\u00e3o \u00e9 <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the newer-generation receptor-selective analog without cortisol\/prolactin signalling, see our <a href=\"https:\/\/medsbase.com\/pt-pt\/ipamorelin\/\">Ipamorelin<\/a> p\u00e1gina de produto. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Agonismo do Recetor GHS-R1a e o Pulso de GH<\/h2>\n<p>What makes GHRP-6 mechanistically distinctive among growth-axis peptides is its <strong>a\u00e7\u00e3o seletiva no recetor secretagogo de hormona de crescimento<\/strong> \u2014 the same receptor activated by endogenous ghrelin \u2014 rather than the GHRH receptor used by sermorelin and CJC-1295. The downstream effect is a pulsatile rather than tonic pattern of GH release in published studies:<\/p>\n<ul>\n<li><strong>Agonismo do recetor GHS-R1a nos somatotrofos<\/strong> \u2014 O GHRP-6 liga-se ao recetor secretagogo da hormona do crescimento tipo 1a (GHS-R1a, tamb\u00e9m chamado recetor da grelina) nos somatotrofos da hip\u00f3fise anterior. A ativa\u00e7\u00e3o do recetor acopla-se \u00e0 G\u03b1<sub>q\/11<\/sub> e \u00e0 fosfolipase C, aumentando o c\u00e1lcio intracelular e desencadeando a exocitose acoplada \u00e0 despolariza\u00e7\u00e3o de ves\u00edculas contendo GH. O sinal \u00e9 amplificado pela supress\u00e3o do t\u00f3nus de somatostatina \u2014 o GHRP-6 atua tanto no somatotrofo como nos neur\u00f3nios hipotal\u00e2micos de somatostatina, produzindo um pulso de GH maior do que a estimula\u00e7\u00e3o direta do somatotrofo por si s\u00f3 preveria.<\/li>\n<li><strong>Sinergia com a GHRH end\u00f3gena<\/strong> \u2014 As vias GHS-R e GHRH-R convergem intracelularmente, mas utilizam diferentes sistemas de segundos mensageiros (PLC\/IP<sub>3<\/sub>\/Ca<sup>2+<\/sup> vs adenylyl cyclase\/cAMP\/PKA), so GHRP-6 and GHRH analogs produce additive or synergistic GH release when combined. This is the rationale for the canonical &#8220;GHRP + GHRH analog&#8221; studies combinations: a GHS such as GHRP-6 paired with a GHRH analog such as <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> ou <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a>. O est\u00edmulo combinado produz pulsos de GH substancialmente maiores do que qualquer um dos compostos isoladamente.<\/li>\n<li><strong>Estimula\u00e7\u00e3o do apetite fora do alvo e sinal modesto de cortisol\/prolactina<\/strong> \u2014 Because GHRP-6 acts on the ghrelin receptor, it inherits ghrelin&#8217;s appetite-stimulating effect \u2014 useful in cachexia studies, but a confound in cleaner GH-axis pharmacology. GHRP-6 also produces a modest increase in cortisol and prolactin secretion. The newer-generation selective analog Ipamorelin was specifically designed to eliminate this cortisol\/prolactin signal while preserving the GH effect \u2014 see the comparison section below.<\/li>\n<\/ul>\n<p>GHRP-6 has a plasma half-life of approximately 30\u201360 minutes, considerably longer than native ghrelin (~10\u201330 minutes) due to the D-amino-acid substitutions that resist proteolytic cleavage. Subcutaneous administration is the most-cited administration route in the published literature; intravenous and intranasal routes are also documented in mechanism-of-action studies. <\/p>\n<h2>Published Evidence<\/h2>\n<p>GHRP-6 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia do eixo da hormona de crescimento<\/strong> \u2014 pulsatile GH dynamics, somatotroph responsiveness, comparative GH-secretagogue studies; benchmark first-generation GHS in published GH-pulse architecture studies (Bowers et al., J Clin Endocrinol Metab; Smith et al., Science 1996)<\/li>\n<li><strong>Appetite and feeding behaviour studies<\/strong> \u2014 ghrelin-axis activation, food-intake assays in rodent models, cachexia models in tumour-bearing animals; canonical tool for separating ghrelin-mediated orexigenic signalling from other appetite pathways<\/li>\n<li><strong>Pituitary function studies<\/strong> \u2014 GH reserve testing in preclinical models, somatotroph hypertrophy \/ hyperplasia, mechanism-of-action data for novel GH secretagogues<\/li>\n<li><strong>Cachexia and wasting syndrome<\/strong> \u2014 caquexia em roedores portadores de tumores, modelos de desgaste associados \u00e0 DPOC, preserva\u00e7\u00e3o de massa magra \/ massa gorda atrav\u00e9s da ativa\u00e7\u00e3o combinada do eixo da GH e do eixo do apetite<\/li>\n<li><strong>Comparative GHS studies<\/strong> \u2014 benchmarking direto contra an\u00e1logos mais recentes, incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/ipamorelin\/\">Ipamorelin<\/a> (seletivo para recetores sem cortisol\/prolactina), hexarelina (GHRP-6 modificado), GHRP-2 (an\u00e1logo alternativo de primeira gera\u00e7\u00e3o) e pequenas mol\u00e9culas GHS oralmente ativas como o MK-677<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 GHS-R expression on cardiomyocytes; published studies on cardiac ischaemia-reperfusion injury and cardiac function in GH-deficient models<\/li>\n<li><strong>Combined GHRP + GHRH use<\/strong> \u2014 protocolos sin\u00e9rgicos de libera\u00e7\u00e3o de GH que combinam GHRP-6 com an\u00e1logos de GHRH como <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> ou <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> for maximal pulsatile GH studies stimulus.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o GHRP-6 se enquadra no panorama de pept\u00eddeos do eixo de crescimento, consulte <a href=\"https:\/\/medsbase.com\/pt-pt\/ipamorelin\/\">Ipamorelin<\/a> como o an\u00e1logo seletivo de recetores de nova gera\u00e7\u00e3o, <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> for long-acting GHRH-axis studies, and <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks GHRP-6 Acetate in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 short-cycle GH-pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo prolongado, estudos de m\u00faltiplas coortes, menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized acetate-salt powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. Because GHRP-6 dose ranges are in the 50\u2013300\u00a0mcg per administration regime, a single 5\u00a0mg vial supports many weeks of use at typical doses. <\/p>\n<h2>Como Compara \u2014 GHRP-6 vs Ipamorelin<\/h2>\n<p>GHRP-6 e <a href=\"https:\/\/medsbase.com\/pt-pt\/ipamorelin\/\">Ipamorelin<\/a> are the canonical first- and third-generation members of the growth hormone secretagogue peptide class, respectively, and are the most-cited head-to-head comparison in published GHS studies. They share the same receptor (GHS-R1a) and produce comparable GH pulses, but differ substantially in receptor selectivity and off-target signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GHRP-6<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Ipamorelin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">6 amino\u00e1cidos (hexapept\u00eddeo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5 amino\u00e1cidos (pentapept\u00eddeo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Gera\u00e7\u00e3o<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS de primeira gera\u00e7\u00e3o (~1984)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS de terceira gera\u00e7\u00e3o (~1998)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS-R1a (recetor de grelina)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS-R1a (recetor de grelina)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Pulso de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Liberta\u00e7\u00e3o puls\u00e1til forte de GH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Liberta\u00e7\u00e3o puls\u00e1til forte de GH (compar\u00e1vel ao GHRP-6)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sinal de apetite<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sim (efeito orexig\u00e9nico semelhante \u00e0 grelina)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Minimal or absent in published studies<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cortisol \/ prolactina<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modest increases (studies-relevant confound)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum aumento mensur\u00e1vel \u2014 o ganho chave de seletividade<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">50\u2013300 mcg, 1\u20133 vezes por dia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013300 mcg, 1\u20133 vezes por dia<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30\u201360 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 horas<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies where the appetite-stimulation signal is a feature (cachexia models, food-intake studies), GHRP-6 is preferred because the orexigenic effect is part of the studies target. For clean GH-axis pharmacology where cortisol and prolactin are confounding variables, Ipamorelin is preferred because the receptor-selectivity gains eliminate those off-target signals. Both are frequently paired with a GHRH analog (such as <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a>) for the canonical synergistic GH-pulse support protocol. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> injetar \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco do p\u00e9ptido (n\u00e3o diretamente sobre o bolo liofilizado). Para um frasco de 5 mg, 2,0 mL de \u00e1gua bacteriost\u00e1tica produzem uma concentra\u00e7\u00e3o de trabalho de 2,5 mg\/mL \u2014 0,04 mL fornece uma dose de investiga\u00e7\u00e3o de 100 mcg; 0,1 mL fornece 250 mcg. Agitar suavemente \u2014 n\u00e3o. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose; 0.1\u00a0mL delivers 250\u00a0mcg. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> agite vigorosamente \u2014 e aguarde 2\u20135 minutos para dissolu\u00e7\u00e3o completa. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve ser l\u00edmpida e incolor. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138\u00a0\u00b0C e utilize dentro de 30 dias para estabilidade \u00f3tima. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam a integridade do p\u00e9ptido. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is GHRP-6 used for in studies?<\/h3>\n<p>GHRP-6 is used in studies investigating the growth hormone axis, pulsatile GH release dynamics, somatotroph responsiveness, ghrelin-axis pharmacology, appetite and feeding behaviour, cachexia and wasting syndromes, and combined GHRP + GHRH synergistic GH-release protocols. It is the canonical first-generation GHS peptide and the structural template from which Ipamorelin and other later-generation analogs were derived. The pharmaceutical-grade GHRP-6 sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Em que \u00e9 que o GHRP-6 difere do Ipamorelina?<\/h3>\n<p>Both act on the same receptor (GHS-R1a, the ghrelin receptor) and produce comparable pulsatile GH release, but they differ substantially in receptor selectivity and off-target signalling. GHRP-6 produces ghrelin-like appetite stimulation and modest increases in cortisol and prolactin. Ipamorelin was specifically designed to eliminate these off-target signals while preserving the GH effect \u2014 it produces minimal appetite signal and no measurable cortisol or prolactin increase in published studies. For clean GH-axis pharmacology, Ipamorelin is preferred; for studies involving appetite as a target, GHRP-6 remains useful. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre GHRP-6 e GHRP-2?<\/h3>\n<p>Both are first-generation hexapeptide growth hormone secretagogues from the Bowers clinical programme. GHRP-2 is somewhat more potent on a per-mg basis and produces slightly less appetite signal than GHRP-6, but the qualitative pharmacology is similar \u2014 both raise cortisol and prolactin modestly. GHRP-6 is the more extensively studied of the pair in published studies and remains the canonical first-generation reference compound. <\/p>\n<h3>What is the typical GHRP-6 dose?<\/h3>\n<p>Published preclinical protocols typically use 50\u2013300\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 2\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.1\u00a0mL equals 250\u00a0mcg. <\/p>\n<h3>O GHRP-6 \u00e9 aprovado pela FDA?<\/h3>\n<p>No. GHRP-6 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h3>Como deve ser armazenado o GHRP-6 Acetato?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para stock de trabalho a curto prazo, ou \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, utilizar no prazo de 30 dias. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam o p\u00e9ptido. Proteger da luz direta em todos os momentos. <\/p>\n<h3>Como devo reconstituir o GHRP-6?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e aguarde 2 a 5 minutos para dissolu\u00e7\u00e3o completa. N\u00e3o <strong>n\u00e3o<\/strong> Agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor. Para um frasco de 5\u00a0mg + 2,0\u00a0mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5\u00a0mg\/mL. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries GHRP-6 Acetate in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Por que o GHRP-6 tamb\u00e9m estimula o apetite?<\/h3>\n<p>O GHRP-6 liga-se ao recetor secretagogo da hormona de crescimento (GHS-R1a) \u2014 o mesmo recetor ativado pela grelina end\u00f3gena. Como a grelina \u00e9 a principal hormona da fome, qualquer agonista do seu recetor herda algum grau de atividade orexig\u00e9nica (estimulante do apetite). Para GHS de primeira gera\u00e7\u00e3o, como o GHRP-6 e o GHRP-2, o efeito no apetite \u00e9 substancial; para an\u00e1logos recetor-seletivos de gera\u00e7\u00f5es posteriores, como o Ipamorelina, o sinal orexig\u00e9nico foi atenuado com sucesso atrav\u00e9s de otimiza\u00e7\u00e3o estrutural. <\/p>\n<h3>Can GHRP-6 be paired with a GHRH analog in studies?<\/h3>\n<p>Yes \u2014 this is the canonical synergistic GH-pulse support protocol. GHRP-6 activates GHS-R1a (PLC\/IP<sub>3<\/sub>\/Ca<sup>2+<\/sup> sinaliza\u00e7\u00e3o) enquanto os an\u00e1logos de GHRH como <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> ou <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> ativa o GHRH-R (sinaliza\u00e7\u00e3o da adenilil ciclase\/cAMP\/PKA). As duas vias convergem nos somatotrofos mas utilizam sistemas de segundos mensageiros diferentes, produzindo uma liberta\u00e7\u00e3o de GH aditiva ou sin\u00e9rgica quando combinadas. <\/p>\n<h3>Does GHRP-6 cause side reported effects?<\/h3>\n<p>The principal on-target effects are GH release and appetite stimulation. Off-target findings include modest cortisol and prolactin increases (the principal studies-relevant confound for GH-axis studies), transient flushing or local injection-site reactions, and (rarely) GHS-R-mediated effects on cardiac function at high doses. The cortisol\/prolactin signal is the main reason newer-generation selective analogs such as Ipamorelin were developed. <\/p>\n<h3>Qual \u00e9 a meia-vida do GHRP-6?<\/h3>\n<p>In preclinical studies, GHRP-6 has a plasma half-life of approximately 30\u201360 minutes following subcutaneous administration. The extended half-life relative to endogenous ghrelin (~10\u201330 min) is due to the two D-amino-acid substitutions (D-Trp at position 2 and D-Phe at position 5) that resist proteolytic cleavage. The GH pulse outlasts plasma clearance because somatotroph desensitisation and receptor downregulation are slower processes. <\/p>\n<h3>How long does GHRP-6 take to show effects in preclinical studies?<\/h3>\n<p>Pulsos agudos de GH s\u00e3o detet\u00e1veis em 15\u201330 minutos ap\u00f3s administra\u00e7\u00e3o subcut\u00e2nea e atingem o pico em 60\u201390 minutos. Os efeitos de estimula\u00e7\u00e3o do apetite na ingest\u00e3o alimentar s\u00e3o mensur\u00e1veis em horas ap\u00f3s administra\u00e7\u00e3o em modelos de roedores. Os efeitos subsequentes na produ\u00e7\u00e3o de IGF-1 e na sinaliza\u00e7\u00e3o do eixo GH a n\u00edvel tecidual acumulam-se ao longo de 1\u20134 semanas de dosagem regular. <\/p>\n<h3>Posso encomendar GHRP-6 para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia GHRP-6 para todo o mundo a partir da nossa rede dedicada de envio de p\u00e9ptidos. Encomendas exclusivas de p\u00e9ptidos qualificam-se para o nosso servi\u00e7o de envio de p\u00e9ptidos independente. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura, com rastreio completo e est\u00e3o cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Growth-Axis, GH-Release, and Anabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Pentap\u00e9ptido seletivo GHS de terceira gera\u00e7\u00e3o \u2014 pulso limpo de GH sem cortisol\/prolactina<\/li>\n<li><a href=\"\/pt-pt\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 canonical GHRH-axis compound<\/li>\n<li><a href=\"\/pt-pt\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/pt-pt\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 An\u00e1logo recombinante de IGF-1 com arginina longa \u2014 a jusante do eixo GH\/IGF<\/li>\n<li><a href=\"\/pt-pt\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore o panorama dos p\u00e9ptidos do eixo GH<\/strong><\/p>\n<p style=\"margin: 0;\">Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, com compostos relacionados do eixo GH incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/ipamorelin\/\">Ipamorelin<\/a> for clean receptor-selective GHS studies, <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> for natural-pulse GHRH use.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Hexapept\u00eddeo GHS de primeira gera\u00e7\u00e3o<br \/>\n\u2705 Agonista do receptor GHS-R1a \/ receptor de grelina<br \/>\n\u2705 Estimula a liberta\u00e7\u00e3o puls\u00e1til de GH<br \/>\n\u2705 Ghrelin-axis appetite studies<br \/>\n\u2705 Sinerg\u00edstico com an\u00e1logos de GHRH<\/p>\n<p><strong>GHRP-6 Acetato<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70956,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6280,5441],"class_list":["post-70733","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ghrp-6","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70733"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70956"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70733"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70733"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70733"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}